Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXER-204 in Chronic Spinal Cord Injury
NCT03989440Phase 2Completed
- Sponsor
- ReNetX Bio
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of axer-204 in cervical spinal cord injury, sponsored by ReNetX Bio. Started Jul 2019; status: completed.
02
Drugs
axer-204
03
Conditions
cervical spinal cord injury
Beyond the preview
Go deeper on NCT03989440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989440.